Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 54

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Pipeline Review, H1 2018

Summary

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Pipeline Review, H1 2018, outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Neuronal acetylcholine receptor subunit alpha 4 or nAChRa4 is a protein encoded by the CHRNA4 gene. It plays a role in fast signal transmission at synapses. Receptors after binding of acetylcholine extensive change conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Nicotine Addiction, Psychiatric Disorders, Smoking Addiction, Alcohol Addiction, Attention Deficit Hyperactivity Disorder (ADHD), Cognitive Disorders, Cognitive Impairment, Major Depressive Disorder, Neurology and Pain.

Furthermore, this report also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)

- The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics and enlists all their major and minor projects

- The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Overview
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Companies Involved in Therapeutics Development
H. Lundbeck AS
NeuroDerm Ltd
Saniona AB
Sopharma AD
Suven Life Sciences Ltd
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Drug Profiles
(nicotine + opipramol) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cytisine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NS-9283 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize CHRNB2 and CHRNA4 for Psychiatric Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize CHRNA4 and CHRNB2 for Neurological and Psychiatric disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize CHRNA4 and CHRNB2 for Nicotine Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize CHRNB2 and CHRNA4 for Smoking Cessation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUVN-911 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
varenicline tartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Dormant Products
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Discontinued Products
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Product Development Milestones
Featured News & Press Releases
May 07, 2018: Achieve Announces Patent Granted on Novel Formulation of Cytisine
Mar 23, 2018: Pfizer Reports Top-Line Results from a Study of CHANTIX/CHAMPIX (varenicline) in Adolescent Smokers
Feb 20, 2018: Achieve Announces Preliminary Data from Cytisine Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study
Nov 14, 2017: Achieve Announces Results of Clinical Study Demonstrating Similar Bioavailability of Cytisine in Fed and Fasted Subjects
Oct 26, 2017: Achieve Announces Exclusive, Long-term Manufacturing Agreement with Sopharma for Clinical and Commercial Supply of Cytisine
Oct 04, 2017: Achieve Announces Advancement of Cytisine Clinical Development Program
Aug 16, 2017: Achieve Announces Initiation of Cytisine Clinical Development Program
Aug 10, 2017: Achieve Announces FDA Acceptance of the Investigational New Drug Application for Cytisine as a Smoking Cessation Treatment
May 25, 2017: Suven Life Sciences announces initiation of Phase 1 Clinical Trial and First Dosing of SUVN-911, a Neuronal Acetylcholine Nicotinic Receptor antagonist for Major Depressive Disorder
Mar 08, 2017: Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Cytisine Symposium at the Annual Society for Research in Nicotine and Tobacco Conference ("SRNT")
Dec 16, 2016: FDA Approves Removal Of Boxed Warning Regarding Serious Neuropsychiatric Events From CHANTIX (varenicline) Labeling
Sep 14, 2016: FDA Advisory Committees Recommend to Remove Boxed Warning in Labeling for Pfizer's Smoking Cessation Therapy, CHANTIX (varenicline)
May 23, 2016: CHAMPIX (Varenicline) European Union Label Updated To Include New Safety And Efficacy Data From The EAGLES Clinical Trial Following Endorsement From CHMP
Apr 22, 2016: CHANTIX/CHAMPIX (Varenicline) Results From The Largest Global Clinical Trial Of Smoking Cessation Medicines Published In The Lancet
Sep 04, 2015: Quit-smoking drug safer than thought
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by H. Lundbeck AS, H1 2018
Pipeline by NeuroDerm Ltd, H1 2018
Pipeline by Saniona AB, H1 2018
Pipeline by Sopharma AD, H1 2018
Pipeline by Suven Life Sciences Ltd, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Discontinued Products, H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
  • Global Antioxidant Vitamins Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100
    The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
  • Global Clavulanate Potassium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
  • Global Amoxicillin Sodium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84
    The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
  • Global Melatonin Supplements Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
  • Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
  • Global Sleeping Pills Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94
    The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Zinc Oral Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
  • Global Zinc Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
  • Global Anti-Infectives Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs